NCT00034242View on ClinicalTrials.gov

High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2002

Study Completion Date

February 29, 2004

Conditions
Spinocerebellar Degenerations
Interventions
DRUG

high-dose intravenous immunoglobulin (IVIG)

Trial Locations (1)

20892

National Institute of Neurological Disorders and Stroke (NINDS), Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH

NCT00034242 - High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration | Biotech Hunter | Biotech Hunter